UNSPSC 51172162: Bietamiverine dihydrochloride

This classification denotes an antispasmotic agent with the molecular formula C19H30N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3XWH8UR3OX, chemically known as bietamiverine dihydrochloride, (+/-)-, but more generally known as bietamiverine dihydrochloride, which bears US NIH Compound Identifier 197773. European Medicines Agency schedules bietamiverine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05825MIG.

Most nations, for tariff purposes, schedule bietamiverine dihydrochloride under HS 29333999. SMILES: CCN(CC)CCOC(=O)C(C1CCCCC1)N2CCCCC2.CL.CL.

UNSPSC 51172162 Bietamiverine dihydrochloride is a Commodity code nominally designating a pharmaceutical active ingredient, but recent state and local procurement activity under this code does not reflect pharmaceutical procurement. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, posted September 25, 2026, is the principal recent opportunity tagged to this code and involves no bietamiverine dihydrochloride procurement. The scope instead encompasses staffing two collection sites in Plano and McKinney, operating an Interactive Voice Response randomized testing notification system, conducting immunoassay screening with LC/MS/MS or GC/MS confirmation, electronic result reporting, and alternative testing methodologies including oral fluid and hair testing. The mismatch between the code's pharmaceutical designation and the actual work being solicited suggests either a data-entry error in the county's tagging or a fundamental misalignment between the code taxonomy and the contracting office's classification.

Activity under this code is sparse. The single recent opportunity on record is Collin County's RFP 2026-327, with proposals due July 23, 2026 at 2:00 p.m., estimated contract value of $600,000 for a two-year term commencing September 1, 2026 with three optional one-year renewals. The scope includes approximately 25,031 annual tests across five-panel, six-panel, and ancillary testing, with pricing submitted on a per-test basis. Evaluation weighting favors vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews worth up to 30 points. Funding derives from Texas Department of Criminal Justice-Community Justice Assistance Division appropriations, subject to annual availability. The anticipated award date is August 10, 2026. No other state or local solicitations under this code appear in the recent-opportunities block; the code shows minimal procurement activity and does not appear to be actively used for its nominal pharmaceutical commodity scope.